Document:

PLEDGE
AND SECURITY AGREEMENT

 

CONFIDENTIAL
DRAFT: FOR DISCUSSION PURPOSES ONLY

 

THIS
PLEDGE AND SECURITY AGREEMENT (the “Pledge”), is made and entered into this ___ day of January 2019, (“Effective
Date”) by and between GENEREX BIOTECHNOLOGY CORPORATION, A Delaware corporation ("Pledgor")
and OLAREGEN THERAPEUTIX INC., a Delaware corporation ("Pledgee").

 

W
I T N E S S E T H:

 

WHEREAS,
Pledgee has sold to Pledgor a majority in interest of the capital stock of Olaregen Therapeutix Inc., a Delaware corporation,
pursuant to the terms contained in that certain Stock Purchase Agreement, dated January __, 2019 made by and between the parties
(“the Purchase Agreement”) pursuant to which Pledgor has sold to Pledgee [3,200,000] shares of Pledgor’s Common
Stock (“Acquired Shares”); and,

 

WHEREAS,
in conjunction with such purchase and consistent with the terms contained in the Purchase Agreement, Pledgor has executed a promissory
note in favor of Pledgee, a copy of which is attached hereto and made a part hereof as Exhibit "A" ("Note");
and,

 

WHEREAS,
the continuing security interest in the Acquired Shares shall be evidenced by this Agreement. Capitalized terms used, but not
defined, in this Agreement have the meanings set forth in the Purchase Agreement; and

 

WHEREAS,
in order to secure the payment of the Note, Pledgor has agreed to pledge the Acquired Shares to Pledgee.

 

NOW,
THEREFORE, in consideration of the mutual covenants, agreements, warranties and representations herein contained, and for
other good and valuable considerations, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree
as follows:

 

1.       As
security for the due and punctual payment of the Note, Pledgor grants to Pledgee a security interest in and a lien on the Acquired
Shares, together with all ownership rights, rights to subscribe, distributions, and other property to which said Pledgor is or
may be entitled to receive on account of the Acquired Shares, whether now or hereafter owned or existing, together with all additions
thereto and substitutions therefor (hereinafter collectively called the "Collateral").

 

2.       Pledgor
agrees that Pledgee shall have, and there is hereby granted to and created in favor of Pledgee, a security interest under the
Uniform Commercial Code of Delaware (hereinafter called the "Code") in and to the collateral hereby assigned and pledged
and intended so to be and in and to the proceeds thereof, both cash and non-cash. Pledgor will faithfully preserve and protect
Pledgee's security interest in the Collateral and the proceeds thereof and will promptly complete and file with the Delaware Secured
Transactions Registry a UCC-1 Form identifying the Acquired Shares as collateral for the Note and giving Pledgee a priority lien.

 

3.       Notwithstanding
the security interest in the Collateral and the proceeds thereof granted to and created in favor of Pledgee by this Agreement,
Pledgor shall have the right, until the occurrence of an event of default as provided in Paragraph 7 hereof, to exercise all voting
rights with respect to the Collateral.

 

    	 	1	 

     

    

 

4.       Pledgor
represents and warrants to Pledgee that, upon the effective date of the Pledge (a) Pledgor is the sole and absolute owner of the
Acquired Shares, (b) the Acquired Shares are free and clear of all pledges, liens, security interests and encumbrances, (c) Pledgor
has the authority and power to execute this Agreement and to grant a security interest in the Collateral in favor of Pledgee,
(d) Pledgor has obtained all necessary consents to enter into this Agreement, and (e) the person executing this Agreement on behalf
of Pledgor is authorized and empowered to do so and will bind Pledgor accordingly.

 

5.       During
the term of this Agreement, Pledgor shall not take any action with respect to the Acquired Shares that is inconsistent with the
provisions or purpose of this Agreement or that would adversely affect the rights of Pledgee. Pledgee shall not assign its interest
in the Collateral, in whole or in part, without the express written consent of Pledgor.

 

6.       Promptly
upon request of Pledgee from time to time, Pledgor will do all such acts and things and will execute and deliver to Pledgee all
such documents as Pledgee may deem necessary or advisable in order to assure Pledgee of its rights granted hereunder, or otherwise
by law, with respect to the Collateral and the proceeds thereof.

 

7.       In
the event Pledgor shall fail to make any payment due under the Note, then, and in any such event, Pledgee shall have such rights
and remedies with respect to the Collateral or any part thereof and the proceeds thereof as are provided for both in the Purchase
Agreement and the Note.

 

8.       Upon
full payment of all sums due by Pledgor to Pledgee under the Note, this Agreement shall terminate and be of no further force and
effect and the UCC-1 Filing shall be withdrawn or terminated by Pledgee within five (5) business days of Pledgor’s full
payment of the Note. Until such time, however, this Agreement shall bind the Pledgor, its successors and assigns, and shall inure
to the benefit of Pledgee, its successors and assigns.

 

9.       No
delay or failure on the part of either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof
or of any other right, power or privilege of either party hereunder; nor shall any single or partial exercise of any such right,
power or privilege preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The
rights and remedies of either party hereunder are cumulative and not exclusive of any rights or remedies which it may otherwise
have.

 

10.       This
Agreement shall be governed by and shall be construed and enforced in accordance with the laws of the State of Delaware.

 

 

 

Remainder
of Page Intentionally Left Blank

Signature
Page to Follow

 

    	 	2	 

     

    

 

 

 

IN
WITNESS WHEREOF, the due execution hereof the day and year first above written.

 

	WITNESS:

         

         

         

        _______________________________
	PLEDGOR:

         

        GENEREX
        BIOTECHNOLOGY 

        CORPORATION
        

        a
        Delaware Corporation

         

         

        By:
        ______________________________

        Joseph
        Moscato

        President
        & Chief Executive Officer

	WITNESS:

         

         

         

        ______________________________
	PLEDGEE:
                                         

         

        OLAREGEN
        THERAPEUTIX INC.

        a
        Delaware corporation

         

         

         

        By:
        ______________________________

        Anthony
        J. Dolisi

        Chief
        Executive Officer and President

 

 

 

    	 	3	 

     

    

EXHIBIT
“A”

 

PROMISSORY
NOTE

 

[See
Attached]

 

 

    	 	4AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT

THIS
AMENDED and RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of this
____ day of January, 2019 by and among Olaregen Therapeutix Inc., a Delaware corporation (the “Company”),
the holders of the Company’s Series A Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”),
which are listed on Schedule A (the “Investors”), Generex Biotechnology Corporation (“Generex”)
and the stockholders of the Company listed on Schedule B (the “Key Holders,” and collectively
with the Investors and Generex, the “Stockholders”).

RECITALS

WHEREAS,
the Investors purchased shares of Series A Preferred Stock pursuant to a Series A Stock Purchase Agreement, dated as of August
29. 2018 (the “Purchase Agreement”), and in connection therewith, the Investors, the Company and the
key Holders entered into an Investor Rights Agreement dated August 29, 2018; and,

WHEREAS,
Generex is purchasing shares of the Company’s Common Stock, pursuant to a Stock Purchase Agreement of even date (the “SPA”);
and,

WHEREAS,
the parties desire to provide the Investors and Generex with the respective right, among other rights, to designate or appoint
members to the Company’s board of directors of the Company (the “Board”) in accordance with the
terms of this Agreement; and,

WHEREAS,
the Second Amended and Restated Certificate of Incorporation of the Company (the “Restated Certificate”)
provides that (a) the holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, will be
entitled to elect one director to the Board and (b) the holders of record of the shares of the Company’s common stock, $0.001
par value per share (“Common Stock”), exclusively and as a separate class, will be entitled to elect
two directors to the Board; and,

WHEREAS,
the Restated Certificate contains additional provisions respecting the rights and obligations of the Series A Preferred Stockholders;
and

WHEREAS,
to the extent that any rights in this Agreement require consent as set forth more fully in in Article Four, Part A, Section
5 of the Restated Certificate, such consent must be obtained prior to implementation of actions under this Agreement.

NOW,
THEREFORE, the parties hereby agree as follows:

1.                 
Voting Provisions Regarding the Board.

1.1             
Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares (as defined below) owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as will be necessary
to ensure that the size of the Board will be set and remain at up to 7 directors. For purposes of this Agreement, the term “Shares”
will mean and include any securities of the Company the holders of which are entitled to vote for members of the Board, including
all shares of Common Stock and Series A Preferred Stock, by whatever name called, now owned or subsequently acquired by a Stockholder,
however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise.

    	 	1	 

     

    

 

1.2             
Board Composition. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over
which such Stockholder has voting control, from time to time and at all times, in whatever manner as will be necessary to ensure
that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent
of the stockholders, subject to Section 8, the following persons will be elected to the Board:

(i)
The President & Chief Executive Officer of the Company, who is currently Anthony Dolisi;

(ii)
One appointee of the Company, who shall be chosen by the directors other than the directors described in Sections 1.2(iii) and
1.2(iv);

(iii)
President & Chief Executive Officer of Generex, who is currently Joseph Moscato, for so long as Generex is the registered
and beneficial owner of not less than Fifty-One Percent (51%) of the issued and outstanding equity securities in the capital of
the Company (the “Generex Director”);

(iv)
One appointee of Generex, for so long as Generex is the is the registered and beneficial owner of not less than Twenty Percent
(20%)

(v)
one appointee of the Series A Preferred Stockholders (the “Series A Preferred Director”); and,

(vi)
two (2) independent directors agreed upon by the Company and Generex, one of whom is currently _______.

It
is further understood and agreed that Anthony Dolisi shall serve as an “observer” of the Purchaser’s Board of
Directors.

To
the extent that any of clauses (i)-(vi) above will not be applicable, any member of the Board who would otherwise have been designated
in accordance with the terms hereof will instead be voted upon by all the stockholders of the Company entitled to vote thereon
in accordance with, and pursuant to, the Restated Certificate.

“Person”
means an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity. “Affiliate”
of a Person means any other Person who, directly or indirectly, controls, is controlled by or is under common control with such
Person, including any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund
or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members
or investment advisers of, or shares the same management company or investment adviser with, such Person.

    	 	2	 

     

    

 

1.3             
Failure to Designate a Board Member. In the absence of any designation from the Persons or groups with the right to designate
a director as specified above, the director previously designated by them and then serving will be reelected if still eligible
and willing to serve as provided herein and otherwise, such Board seat will remain vacant.

1.4             
Removal of Board Members. Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as will be necessary
to ensure that:

(a)              
no director elected pursuant to Subsection 1.2 or 1.3 of this Agreement may be removed from office unless (i) such
removal is directed or approved by the affirmative vote of the Person(s) or Stockholders entitled to designate or approve that
director; or (ii) the Person(s) originally entitled to designate or approve such director pursuant to Subsection 1.2
is no longer so entitled to designate or approve such director;

(b)              
any vacancies created by the resignation, removal or death of a director elected pursuant to Subsection 1.2 or 1.3 will
be filled pursuant to the provisions of this Section 1; and

(c)              
upon the request of any party entitled to designate a director as provided in Subsection 1.2(a) or 1.2(b),
respectively, to remove such director, such director will be removed.

All
Stockholders agree to execute any written consents required to perform the obligations of this Section 1, and the
Company agrees at the request of any Person or group entitled to designate directors to call a special meeting of stockholders
for the purpose of electing directors.

1.5             
No Liability for Election of Recommended Directors. No Stockholder, nor any Affiliate of any Stockholder, will have any
liability as a result of designating a Person for election as a director for any act or omission by such designated Person in
his or her capacity as a director of the Company, nor will any Stockholder have any liability as a result of voting for any such
designee in accordance with the provisions of this Agreement.

1.6             
Compensation and Insurance. The Company shall reimburse members of the Board of Directors for the customary and reasonable
expenses of attending the meetings of the Board. The Company shall offer Independent Directors compensation reasonable and customary
in light of the Company’s size, complexity, stage of business and industry. Within thirty (30) days after the date of this
Agreement, the Company will bind Directors and Officers liability with a carrier, in an amount reasonably satisfactory to the
Series A Preferred Director and the Generex Director.

2.                 
Vote to Increase Authorized Common Stock. Each Stockholder agrees to vote or cause to be voted all Shares owned
by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner
as will be necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be
sufficient shares of Common Stock available for conversion of all of the shares of Series A Preferred Stock outstanding at any
given time.

    	 	3	 

     

    

 

3.                 
Market Stand-Off Agreement. Each Stockholder hereby agrees that it will not, without the prior written consent of
the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the
Company of shares of its Common Stock or any other equity securities under the Securities Act of 1933, as amended (the “Securities
Act”) on a registration statement on Form S-1 or Form S-3 and ending on the date specified by the Company and the
managing underwriter (such period not to exceed 180 days in the case of the IPO, or 90 days in the case of any registration other
than the IPO, or, in either case, such other period as may be requested by the Company or an underwriter to accommodate regulatory
restrictions on (x) the publication or other distribution of research reports, and (y) analyst recommendations and opinions, including
the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto),
(a) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell;
grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common
Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such
shares or any such securities are then owned by the Stockholder or are thereafter acquired) or (b) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities,
whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common Stock or other securities,
in cash, or otherwise. The foregoing provisions of this Section 3 will not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Stockholder
or the immediate family of the Stockholder, provided that the trustee of the trust agrees to be bound in writing by the restrictions
set forth herein, and provided further that any such transfer will not involve a disposition for value, and will be applicable
to the Stockholders only if all officers and directors are subject to the same restrictions. The underwriters in connection with
such registration are intended third-party beneficiaries of this Section 3 and will have the right, power and authority
to enforce the provisions hereof as though they were a party hereto. Each Stockholder further agrees to execute such agreements
as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section
3 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any
or all of such agreements by the Company or the underwriters will apply pro rata to all Company Stockholders that are subject
to such agreements, based on the number of shares subject to such agreements, except that, notwithstanding the foregoing, the
Company and the underwriters may, in their sole discretion, waive or terminate these restrictions with respect to up to 5% of
the shares of the Common Stock. The Company may impose stop-transfer instructions and may stamp each certificate with a legend
consistent with the foregoing restriction until the end of such 180-day period.

    	 	4	 

     

    

 

4.                 
Repurchase; Mandatory Repayment.

4.1             
Series A Preferred Stock Repurchase. At any time and from time to time between the first anniversary of August 29, 2018,
and the 30-month anniversary of August 29, 2018, the Company will have the option, but not the obligation, to repurchase at the
Repurchase Price all or any portion of the Series A Preferred Stock up to the fewer of 177,805 or 30% of the Series A Preferred
Stock then issued and outstanding by delivering written notice (the “Repurchase Notice”) to each Investor
(the “Repurchase Option”). The Repurchase Notice will provide (i) that the Company is exercising its
Repurchase Option; (ii) the number of shares of Series A Preferred Stock the Company is repurchasing, and (iii) the aggregate
Repurchase Price to be paid for the Repurchased Shares. The Repurchase Notice will be accompanied by a check made out in the name
of each holder, or other immediately available funds will be provided, for an amount equal to the Repurchase Price paid to such
holder. Upon delivery of the Repurchase Notice and the Repurchase Price, the Repurchased Shares so repurchased and all rights
and interests therein or relating thereto will be deemed cancelled and the Company will have the right to retain and transfer
to its own name the Repurchased Shares. The Repurchase Option set forth in this Section may be assigned by the Company in whole
or in part in its sole discretion. The Investors will surrender the certificates representing the Repurchased Shares. A new certificate
representing the number of Series A Preferred Shares less the Repurchased Shares will be issued to the Investor thereof without
cost to such holder within 3 business days after surrender of the certificate representing the Repurchased Shares. The Company
will be required to redeem the Repurchased Shares from the holders of Series A Preferred Shares ratably in accordance with each
holder’s percentage ownership of the Series A Preferred Stock. For purposes hereof, the “Repurchase Price”
means $8.00 per share of Series A Preferred Stock, which will be subject to adjustment as provided herein.

4.2             
No Rights after Repurchase. No Repurchased Share is entitled to any dividends declared after the date on which the Repurchase
Price of such Repurchased Share is paid in full to the holder thereof, and, for purposes of clarity, unless and until the Repurchase
Price has been actually paid for a Repurchased Share, the holder of such share of Series A Preferred Stock will maintain all voting
rights with respect thereto. On the date the Repurchase Price is actually paid to the holder, all rights of the holder of such
Repurchased Share will cease, and such Repurchased Share will no longer be deemed to be outstanding.

4.3             
Repurchased or Otherwise Acquired Shares. Any shares of Series A Preferred Stock that are repurchased or otherwise acquired
by the Company will be considered authorized but unissued shares.

4.4             
Mandatory Repayment if No Repurchase. If the Company fails to exercise all or any portion of the Repurchase Option, the
Investors holding at least a majority of the Series A Preferred Stock then issued and outstanding may elect, at their option,
to require the Company to pay to the holders of Series A Preferred Stock $1,422,438.00, less any amount paid for the Repurchased
Shares (the “Mandatory Repayment Amount”), by delivering written notice of such request to the Company.
The Company will be required to pay the Mandatory Repayment Amount ratably to the holders of Series A Preferred Stock (including
to the non-initiating holders pursuant to the immediately preceding sentence) in accordance with each holder’s percentage
ownership of the Series A Preferred Stock.

    	 	5	 

     

    

 

5.                 
Preemptive Rights.

5.1             
Preemptive Rights. If, at any time and from time to time, the Company should desire to issue any shares of Common Stock,
shares of Series A Preferred Stock or any other class of capital stock of the Company, whether or not now authorized, securities
of any type that are convertible into shares of such capital stock or options, warrants, debt instruments or rights to acquire
shares of such capital stock (“New Securities”), it will give Generex and each Investor (collectively,
the “Rights Holders”) the first right to purchase its “Proportionate Portion”
of New Securities, determined by multiplying the total number of shares of New Securities available for purchase by a fraction,
the numerator of which is the number of shares of Common Stock, including shares of Common Stock issuable upon conversion of the
Series A Preferred Stock, held by such Rights Holder, and the denominator of which is the number of shares of Common Stock actually
issued and outstanding plus the number of shares of Common Stock issuable on the exercise, conversion or exchange of all then-exerciseable
warrants, options, subscriptions, or purchase rights with respect to shares of Common Stock and any securities convertible into
or exchangeable for shares of Common Stock or any exerciseable warrants, options, subscriptions, or purchase rights with respect
to such convertible securities (including the number of shares of Common Stock issuable on the conversion of the outstanding shares
of Series A Preferred Stock) on the same terms as the Company is willing to sell such New Securities to any other person or entity.
“New Securities” will not include: (A) securities offered to the public pursuant to a registration statement under
the Securities Act; (B) Common Stock, options or other rights to acquire shares of Common Stock (as adjusted for stock dividends,
splits, combinations and the like with respect to the Common Stock) (and the issuance of shares of Common Stock upon exercise
thereof), issued pursuant to stock incentive plans or grants to officers, directors, employees and consultants approved by the
Board; (C) the Series A Preferred Shares pursuant to the Purchase Agreement and shares of Series A Preferred Shares and Common
Stock issuable upon conversion or as dividends of such Preferred Shares; (D) the common Stock issuable pursuant to the SPA,
(E) Common Stock issued or issuable as a result of an adjustment pursuant to Section 4.3 of the Restated Certificate;
and (F) Common Stock or securities convertible into or exercisable for Common Stock, if approved by the holder or holders of Generex
and a majority of the shares of Series A Preferred Stock then outstanding, in each case as securities excluded from the conversion
price adjustment provisions provided for herein.

5.2             
Notice. Prior to any sale or issuance by the Company of any New Securities, the Company will notify each Rights Holder
in writing of its intention to sell and issue such securities, setting forth the terms under which it proposes to make such sale
(the “Participation Notice”). Within 10 business days after receipt of the Participation Notice (the
“Exercise Period”), each Rights Holder will notify the Company whether such holder desires to exercise
its option to purchase the Proportionate Portion (or any part thereof) of the New Securities so offered. Within 2 business days
after the expiration of the Exercise Period, the Company will notify in writing each Rights Holder who elected to purchase its
entire Proportionate Portion of the New Securities (each, an “Electing Holder”) of the aggregate number
of offered New Securities that any of the Investors chose not to purchase (the “Over-Allotment Notice”).
Each Electing Holder will have the option to purchase, on a pro rata basis (based on the Common Stock, including shares of Common
Stock issuable upon conversion of the Series A Preferred Stock, held by all of the Electing Holders), its portion of the New Securities
such other Rights Holders elected not to purchase (the “Over-Allotment Option”). Each Electing Holder
will notify the Company within 5 business days after receipt of the Over-Allotment Notice (the “Over-Allotment Period”)
whether such Electing Holder desires to exercise its Over-Allotment Option. In the event that the Electing Holders purchase all
of the New Securities to be offered by the Company under the Participation Notice, then a closing of the sale and issuance of
the New Securities to the Electing Holders will occur no later than the date set forth in the Participation Notice.

    	 	6	 

     

    

 

5.3             
Sale of Shares. After the expiration of the Over-Allotment Period, the Company may, during a period of 90 days immediately
following the end of the Over-Allotment Period, sell and issue any New Securities not purchased pursuant to this Section to another
person or entity, upon the same terms and conditions as those set forth in the Participation Notice. In the event the Company
has not sold the New Securities within said 90-day period, the Company will not thereafter issue or sell any New Securities without
first offering such securities to the Investors in the manner provided above.

6.                 
Confidentiality. Each Rights Holder agrees that such Investor will keep confidential and will not disclose, divulge, or
use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company
pursuant to the terms of this Agreement and the Purchase Agreement (including notice of the Company’s intention to file
a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other
than as a result of a breach of this Section 6 by such Investor), (b) is or has been independently developed or conceived
by such Investor without use of the Company’s confidential information, (c) is or has been made known or disclosed to such
Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; or (d)
is required to be disclosed by Generex pursuant to its reporting obligations under applicable securities law. provided,
however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; or
(ii) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.

7.                 
Remedies.

7.1             
Irrevocable Proxy and Power of Attorney. Each party to this Agreement hereby constitutes and appoints as the proxies of
the party and hereby grants a power of attorney to the President of the Company with respect to the matters set forth herein,
including, without limitation, votes to increase authorized shares pursuant to Section 2 hereof, and hereby authorizes
the President to represent and vote, if and only if the party (i) fails to vote, or (ii) attempts to vote (whether by
proxy, in person or by written consent) in a manner that is inconsistent with the terms of this Agreement, all of such party’s
Shares in favor of the election of persons as members of the Board determined pursuant to and in accordance with the terms and
provisions of this Agreement or the increase of authorized shares pursuant to and in accordance with the terms and provisions
of Section 2 of this Agreement or to take any action reasonably necessary to effect Sections 2 of this Agreement.
Each of the proxy and power of attorney granted pursuant to this Subsection 7.2 is given in consideration of the agreements
and covenants of the Company and the parties in connection with the transactions contemplated by this Agreement and, as such,
each is coupled with an interest and will be irrevocable unless and until this Agreement terminates or expires pursuant to Section
9 hereof. Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the Shares and
will not hereafter, unless and until this Agreement terminates or expires pursuant to Section 9 hereof, purport to grant
any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter
into any agreement (other than this Agreement), arrangement or understanding with any person, directly or indirectly, to vote,
grant any proxy or give instructions with respect to the voting of any of the Shares, in each case, with respect to any of the
matters set forth herein.

    	 	7	 

     

    

 

7.2             
Specific Enforcement. Each party acknowledges and agrees that each party hereto will be irreparably damaged in the event
any of the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise
breached. Accordingly, it is agreed that each of the Company and the Stockholders will be entitled to an injunction to prevent
breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted
in any court of the United States or any state having subject matter jurisdiction.

7.3             
Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any party, will be cumulative
and not alternative.

8.                 
“Bad Actor” Matters.

8.1             
Definitions. For purposes of this Agreement:

(a)              
“Company Covered Person” means, with respect to the Company as an “issuer” for purposes
of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

(b)              
“Disqualified Designee” means any director designee to whom any Disqualification Event is applicable,
except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable.

(c)              
“Disqualification Event” means a “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii)
promulgated under the Securities Act.

(d)              
“Rule 506(d) Related Party” means, with respect to any Person, any other Person that is a beneficial
owner of such first Person’s securities for purposes of Rule 506(d) under the Securities Act. 

8.2             
Representations. Each Person with the right to designate or participate in the designation of a director pursuant to this
Agreement hereby represents that (i) such Person has exercised reasonable care to determine whether any Disqualification Event
is applicable to such Person, any director designee designated by such Person pursuant to this Agreement or any of such Person’s
Rule 506(d) Related Parties, except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3)
is applicable and (ii) no Disqualification Event is applicable to such Person or, to such Person’s knowledge, any Board
member designated by such Person pursuant to this Agreement or any of such Person’s Rule 506(d) Related Parties, except,
if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable.

    	 	8	 

     

    

 

8.3             
Covenants. Each Person with the right to designate or participate in the designation of a director pursuant to this Agreement
covenants and agrees (i) not to designate or participate in the designation of any director designee who, to such Person’s
knowledge, is a Disqualified Designee, (ii) to exercise reasonable care to determine whether any director designee designated
by such person is a Disqualified Designee, (iii) that in the event such Person becomes aware that any individual previously designated
by any such Person is or has become a Disqualified Designee, such Person will as promptly as practicable take such actions as
are necessary to remove such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified
Designee, and (iv) to notify the Company promptly in writing in the event a Disqualification Event becomes applicable to such
Person or any of its Rule 506(d) Related Parties, or, to such Person’s knowledge, to such Person’s initial designee
named in Section 1, except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or
(d)(3) is applicable.

9.                 
Term. This Agreement will be effective as of the date hereof and will continue in effect until and will terminate
upon the earliest to occur of (a) the consummation of the Company’s first underwritten public offering of its Common Stock
(other than a registration statement relating either to the sale of securities to employees of the Company pursuant to its stock
option, stock purchase or similar plan or an SEC Rule 145 transaction); (b) the consummation of a Fundamental Change of the Company;
and (c) termination of this Agreement in accordance with Subsection 10.8 below.

10.             
Drag Along Rights

10.1         
Definitions. A “Sale of the Company” shall mean either: (a) a transaction or series of related
transactions in which a Person, or a group of related Persons, acquires from Stockholders shares of the Company’s capital
stock representing more than fifty percent (50%) of the outstanding voting power of the Company (a “Stock Sale”);
or (b) a transaction that qualifies as a “Fundamental Change” as defined in the Restated Certificate. .

10.2         
Actions to be Taken. In the event that (i) Generex and the holders of at least fifty percent (50%) of the outstanding Series
A Preferred Shares (collectively, the “Selling Investors”) and (ii) the Board approve a Sale of the Company
in writing, specifying that this Section 10 shall apply to such transaction, then each Stockholder and the Company hereby agree:

(a)              
if such transaction requires stockholder approval, with respect to shares of the Company’s capital stock that such Stockholder
owns or over which such Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent,
as applicable) all shares in favor of, and adopt, such Sale of the Company (together with any related amendment to the Certificate
required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably
be expected to delay or impair the ability of the Company to consummate such Sale of the Company;

(b)              
if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock beneficially held by such Stockholder
as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their shares, and, except
as permitted in Subsection 10.3 below, on the same terms and conditions as the Selling Investors;

    	 	9	 

     

    

 

(c)              
to execute and deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably
be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 10,
including, without limitation, executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger
agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer
(free and clear of impermissible liens, claims and encumbrances), and any similar or related documents

(d)              
not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any shares of the Company
owned by such party or Affiliate in a voting trust or subject any shares to any arrangement or agreement with respect to the voting
of such shares, unless specifically requested to do so by the acquiror in connection with the Sale of the Company;

(e)              
to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time with respect to
such Sale of the Company;

(f)               
if the consideration to be paid in exchange for the shares pursuant to this Section 10 includes any securities and due
receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities
or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to any Stockholder of any
information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited
investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such
Stockholder in lieu thereof, against surrender of the shares which would have otherwise been sold by such Stockholder, an amount
in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Stockholder would otherwise
receive as of the date of the issuance of such securities in exchange for the shares; and

(g)              
in the event that the Selling Investors, in connection with such Sale of the Company, appoint a stockholder representative (the
“Stockholder Representative”) with respect to matters affecting the Stockholders under the applicable definitive
transaction agreements following consummation of such Sale of the Company, (x) to consent to (i) the appointment of such Stockholder
Representative, (ii) the establishment of any applicable escrow, holdback, expense or similar fund in connection with any indemnification
or similar obligations, and (iii) the payment of such Stockholder ‘s pro rata portion (from the applicable escrow, holdback
or expense fund or otherwise from the proceeds of the Sale of the Company) of any and all reasonable fees and expenses to such
Stockholder Representative in connection with such Stockholder Representative’s services and duties in connection with such
Sale of the Company and its related service as the representative of the Members, and (y) not to assert any claim or commence
any suit against the Stockholder Representative or any other Stockholder with respect to any action or inaction taken or failed
to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or
willful misconduct.

10.3         
Exceptions. Notwithstanding the foregoing, a Member will not be required to comply with Subsection 10 above in connection
with any proposed Sale of the Company (the “Proposed Sale”), unless:

    	 	10	 

     

    

 

(a)              
any representations and warranties to be made by such Stockholder in connection with the Proposed Sale are limited to customary
representations and warranties related to authority, ownership and the ability to convey title to such Stockholder’s shares,
including, but not limited to, customary representations and warranties that (i) the Stockholder holds all right, title and interest
in and to the shares such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of
the Member in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be entered into
by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder
in accordance with their respective terms; and (iv) neither the execution and delivery of documents to be entered into in connection
with the transaction, nor the performance of the Stockholder obligations thereunder, will cause a breach or violation of the terms
of any agreement, law or judgment, order or decree of any court or governmental agency applicable to such Stockholder;

(b)              
the Stockholder shall not be liable for the inaccuracy of any representation or warranty made by any other Person in connection
with the Proposed Sale or the noncompliance by any other Person with any covenant or agreement in connection with the Proposed
Sale, other than the Company (except to the extent that funds may be paid out of an escrow or holdback established to cover breach
of representations, warranties and covenants of the Company as well as breach by any member of any of identical representations,
warranties and covenants provided by all Stockholders)

(c)              
the liability for indemnification, if any, of such Stockholder in the Proposed Sale and for the inaccuracy of any representations
and warranties made by the Company or its Stockholders in connection with such Proposed Sale, is several and not joint with any
other Person (except to the extent that funds may be paid out of an escrow or holdback established to cover breach of representations,
warranties and covenants of the Company as well as breach by any Stockholder of any of identical representations, warranties and
covenants provided by all members), is pro rata in proportion to, and does not exceed, in the aggregate for all indemnification
claims, the amount of consideration paid to such Stockholder in connection with such Proposed Sale

11.             
IPO. Upon the earlier of (i) the second anniversary of the Closing Date, and (ii) the date upon which audited financial
statements disclose Company EBITDA of not less than Ten Million Dollars ($10,000,000.00) for the 12-month period ending on the
date of such financial statements, the Company shall have the absolute right to file a registration statement with the Securities
and Exchange Commission for an initial public offering of its common stock and list its common shares of stock on a national stock
exchange in the United States (an “Exchange Listing”). Should that occur, the Company shall have the option to acquire
the Shares of common stock purchased by Generex pursuant to the SPA (and any shares issued as dividends on or upon recapitalization
of such Common Stock) (the “Purchased Shares”) on the following terms and conditions:

11.1         
At any time during the period commencing thirty (30) trading days after the effective date of the Exchange Listing and ending
ninety (90) trading days after such effective date, the Company, upon written notice to the Generex, may elect to purchase up
to thirty-five percent (35%) of the Purchased Shares of which the Purchaser is the registered and beneficial owner as at the date
of receipt of such notice.

    	 	11	 

     

    

 

11.2         
The per-share purchase price in respect of any Purchased Shares purchased by the Company pursuant to sub-paragraph (a) above will
be equal to the VWAY of the Company’s common shares for the thirty (30) trading days following the effective date of the
Exchange Listing. For purposes of this Agreement, “VWAP” means, for any date, the daily volume weighted average price
for such date (or the nearest preceding date) of the relevant securities on the trading market where such securities are then
listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9 a.m. New York City time to 4:02 p.m. New York City
time.

12.             
Miscellaneous.

12.1         
Additional Parties.

(a)              
Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Series A Preferred Stock
after the date hereof, as a condition to the issuance of such shares the Company will require that any purchaser of such shares
become a party to this Agreement by executing and delivering (i) the Adoption Agreement attached to this Agreement as Exhibit
A, or (ii) a counterpart signature page hereto agreeing to be bound by and subject to the terms of this Agreement as an Investor
and Stockholder hereunder. In either event, each such person will thereafter be deemed an Investor and Stockholder for all purposes
under this Agreement.

(b)              
In the event that after the date of this Agreement, the Company enters into an agreement with any Person to issue shares of capital
stock to such Person (other than to a purchaser of Series A Preferred Stock described in Subsection 10.1(a) above), following
which such Person will then hold outstanding capital stock of the Company, then, the Company will cause such Person, as a condition
precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption Agreement in the form
attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a Stockholder and thereafter
such person will be deemed a Stockholder for all purposes under this Agreement.

12.2         
Transfers. Each transferee or assignee of any Shares subject to this Agreement will continue to be subject to the terms
hereof, and, as a condition precedent to the Company’s recognition of such transfer, each transferee or assignee will agree
in writing to be subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially
in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any transferee, such
transferee will be deemed to be a party hereto as if such transferee were the transferor and such transferee’s signature
appeared on the signature pages of this Agreement and will be deemed to be an Investor and Stockholder, or Key Holder and Stockholder,
as applicable. The Company will not permit the transfer of the Shares subject to this Agreement on its books or issue a new certificate
representing any such Shares unless and until such transferee will have complied with the terms of this Subsection 10.2.
Each certificate, instrument, or book entry representing the Shares subject to this Agreement if issued on or after the date of
this Agreement will be notated by the Company with the legend set forth in Subsection 10.12.

    	 	12	 

     

    

 

12.3         
Successors and Assigns. The terms and conditions of this Agreement will inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

12.4         
Governing Law; Jurisdiction and Venue. This Agreement shall be governed by the Laws of the State of New York without giving
effect to any choice of law or conflict of law provision or rule. All Actions arising out of or relating to this Agreement shall
be heard and determined in any state or federal court sitting in the State of New York, County of New York. Each of the parties
to this Agreement irrevocably submits to the exclusive jurisdiction of the state courts of New York and to the jurisdiction of
the United States District Court for the Southern District of New York for the purpose of any Action arising out of or relating
to this Agreement. .

12.5         
Counterparts. This Agreement may be executed in 2 or more counterparts, each of which will be deemed an original, but all
of which together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail or
other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid
and effective for all purposes.

12.6         
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

12.7         
Notices.

(a)              
All notices and other communications given or made pursuant to this Agreement will be in writing and will be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic
mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (iii) 3 business days after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next business day delivery, with written verification of receipt. All communications will be sent to the respective
parties at their address as set forth on Schedule A or Schedule B hereto, or to such email address or address as
subsequently modified by written notice given in accordance with this Subsection 10.7. If notice is given to the Company,
copies will be sent to:

	If
                                         to the Company:

        Olaregen
        Therapeutix Inc.

        1001
        Avenue of the Americas 2nd Fl

        New
        York, NY 10018

        Attn:
        Wesley Ramjeet

        Wesley.ramjeet@olaregen.com
	With
                                         a copy to:

        Freeborn
        & Peters LLP

        311
        South Wacker Drive, Suite 3000

        Chicago,
        IL 60606

        Attn:
        Jeff Mattson

        jmattson@freeborn.com

         

         

 

    	 	13	 

     

    

 

(b)              
Consent to Electronic Notice. Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant
to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by
electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address set forth
below such Investor’s or Key Holder’s name on the Schedules hereto, as updated from time to time by notice to the
Company, or as on the books of the Company. Each Investor and Key Holder agrees to promptly notify the Company of any change in
its electronic mail address, and that failure to do so will not affect the foregoing.

12.8         
Consent Required to Amend, Modify, Terminate or Waive. This Agreement may be amended, modified or terminated (other than
pursuant to Section 9) and the observance of any term hereof may be waived (either generally or in a particular instance
and either retroactively or prospectively) only by a written instrument executed by (a) the Company, (b) the Key Holders holding
a majority of the Shares then held by the Key Holders then providing services to the Company as officers, employees or consultants,
(c) the holders of at least two-thirds (2/3) of the shares of Common Stock issued or issuable upon conversion of the shares of
Series A Preferred Stock held by the Investors, voting together as a single class, (d) the holders of at least Fifty Percent (50%)
of the Series A Preferred Stock, and (e) Generex. Notwithstanding the foregoing:

(a)              
this Agreement may not be amended, modified or terminated and the observance of any term of this Agreement may not be waived with
respect to any Investor or Key Holder without the written consent of such Investor or Key Holder unless such amendment, modification,
termination or waiver applies to all Investors or Key Holders, as the case may be, in the same fashion; and

(b)              
the provisions of Subsection 1.2(a) and this Subsection 10.8 may not be amended, modified, terminated or waived
without the written consent of the Company;

(c)              
the consent of the Key Holders will not be required for any amendment, modification, termination or waiver if such amendment,
modification, termination, or waiver either (A) is not directly applicable to the rights of the Key Holders hereunder; or (B) does
not adversely affect the rights of the Key Holders in a manner that is different than the effect on the rights of the other parties
hereto;

(d)              
Schedule A hereto may be amended by the Company from time to time to add information regarding additional Purchasers (as
defined in the Purchase Agreement) without the consent of the other parties hereto; and

(e)              
any provision hereof may be waived by the waiving party on such party’s own behalf, without the consent of any other party.

The
Company will give prompt written notice of any amendment, modification, termination, or waiver hereunder to any party that did
not consent in writing thereto. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 10.8
will be binding on each party and all of such party’s successors and permitted assigns, whether or not any such party,
successor or assignee entered into or approved such amendment, modification, termination or waiver. For purposes of this Subsection 10.8,
the requirement of a written instrument may be satisfied in the form of an action by written consent of the Stockholders circulated
by the Company and executed by the Stockholder parties specified, whether or not such action by written consent makes explicit
reference to the terms of this Agreement.

    	 	14	 

     

    

 

12.9         
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, will impair any such right, power or remedy of such non-breaching
or non-defaulting party nor will it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor will any waiver of any single breach or default be deemed a waiver
of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and will be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement or by law or otherwise afforded to any party, will be cumulative and not alternative.

12.10     
Severability. The invalidity or unenforceability of any provision hereof will in no way affect the validity or enforceability
of any other provision.

12.11     
Entire Agreement. This Agreement (including the Schedules and Exhibits hereto) constitutes the full and entire understanding
and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating
to the subject matter hereof existing between the parties is expressly canceled.

12.12     
Share Certificate Legend. Each certificate, instrument, or book entry representing any Shares issued after the date hereof
will be notated by the Company with a legend reading substantially as follows:

“THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO TRANSFER OF THE SHARES MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

“The
SALE, PLEDGE, HYPOTHECATION, OR TRANSFER OF THE SHARES REPRESENTED HEREBY IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY, THE
TERMS AND CONDITIONS OF AN INVESTOR RIGHTS agreement, AS MAY BE AMENDED FROM TIME TO TIME, BY AND AMONG THE STOCKHOLDER, THE COMPANY
AND CERTAIN OTHER HOLDERS OF STOCK OF THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY
OF THE COMPANY. BY ACCEPTING ANY INTEREST IN SUCH SHARES, THE PERSON ACCEPTING SUCH INTEREST WILL BE DEEMED TO AGREE TO, AND WILL
BECOME BOUND BY, ALL THE PROVISIONS OF THE AFOREREFERENCED AGREEMENT INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP
SET FORTH THEREIN.”

    	 	15	 

     

    

 

The
Company, by its execution of this Agreement, agrees that it will cause the certificates, instruments, or book entry evidencing
the Shares issued after the date hereof to be notated with the legend required by this Subsection 10.12 of this Agreement,
and it will supply, free of charge, a copy of this Agreement to any holder of such Shares upon written request from such holder
to the Company at its principal office. The parties to this Agreement do hereby agree that the failure to cause the certificates,
instruments, or book entry evidencing the Shares to be notated with the legend required by this Subsection 10.12 herein
and/or the failure of the Company to supply, free of charge, a copy of this Agreement as provided hereunder will not affect the
validity or enforcement of this Agreement.

12.13     
Stock Splits, Stock Dividends, etc. In the event of any issuance of Shares or the voting securities of the Company hereafter
to any of the Stockholders (including in connection with any stock split, stock dividend, recapitalization, reorganization, or
the like), such Shares will become subject to this Agreement and will be notated with the legend set forth in Subsection 10.12.

12.14     
Manner of Voting. The voting of Shares pursuant to this Agreement may be effected in person, by proxy, by written consent
or in any other manner permitted by applicable law. For the avoidance of doubt, voting of the Shares pursuant to the Agreement
need not make explicit reference to the terms of this Agreement.

12.15     
Further Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other,
and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further
action as the other party may reasonably request in order to carry out the intent of the parties hereunder.

12.16     
Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT, THE SHARES OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING
OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY
HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

    	 	16	 

     

    

 

12.17     
Costs of Enforcement. If any party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings,
the non-prevailing party will pay all costs and expenses incurred by the prevailing party, including all reasonable attorneys’
fees.

12.18     
Aggregation of Stock. All Shares held or acquired by a Stockholder and/or its Affiliates will be aggregated together for
the purpose of determining the availability of any rights under this Agreement, and such Affiliated persons may apportion such
rights as among themselves in any manner they deem appropriate

12.19     
Special Covenant. The Company and Generex will negotiate in good faith to enter into a formal license and distribution
agreement within 30 days after the date of this Agreement, to provide Generex the non-exclusive right to distribute the Company’s
products in the United States via Generex’s direct-to-patient and management services organizations at contracted prices
equal to one percent (1%) above the applicable Federal Government Prices..

 

Remainder
of Page Intentionally Left Blank; Signature Page follows.]

 

    	 	17	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of the date first written above.

 

	COMPANY:	 	OLARGEN THERAPEUTIX INC., a Delaware corporation
	 	 	 
	 	 	By:
	 	 	Anthony Dolisi, CEO

 

    	 	18	 

     

    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Company
Signature Page to Investor Rights Agreement

 

    	 

    	 

    

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

 

INDIVIDUAL
KEY HOLDERS:

Signature:

Name:

 

ENTITY
KEY HOLDERS:

Entity
Name: 

By

Name:

Title:

 

 

 

 

 

 

 

Key
Holder Signature Page to Amended and Restated Investor Rights Agreement

 

    	 

    	 

    

WITNESS
WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	INVESTOR:

         
	CREEK
                                         MOUNTAIN PARTNERS, LLC

         

        By:
        ___________________________________

        Print
        Name: ____________________________

        Title:
        _________________________________

        Address:

        c/o
        Medcatalyst, LLC

        PO
        Box 1445

        Exmore,
        VA 23350

        Attn:
        Ronald Matthews

        Email:
        matthewsrf@gmail.com

         

         

 

 

 

 

 

 

 

 

 

 

 

 

Investor
Signature Page to Amended and Restated Investor Rights Agreement

    	 

    	 

    

WITNESS
WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	GENEREX
                                         BIOTECHNOLOGY CORPORATION

         

        By:
        ___________________________________

        Print
        Name: ____________________________

        Title:
        _________________________________

        Address:

        10102
        USA TODAY WAY

        MIRAMAR,
        FL 33025

        Attn:
        Joseph Moscato

        Email:
        jmoscato@generex.com

         

         

 

    	 

    	 

    

 

SCHEDULE
A

INVESTORS

 

	Name
    and Address	Phone	Email

Creek
Mountain Partners, LLC (757) 894-4329 matthewsrf@gmail.com

c/o
Medcatalyst, LLC

PO
Box 1445

Exmore,
VA 23350

 

 

 

 

    	 

    	 

    

 

SCHEDULE
B

KEY
HOLDERS

	Name	Number
    of Shares Held
	Anthony
    Dolisi	649,808
	Cliff
    Keeling	250,000
	Wesley
    Ramjeet	60,000
	Michelle
    Starr	150,000
	Frank
    Dolisi	78,200
	Scott
    Emmens	58,992
	Aniket
    Kaloti	 100,200
	The
    Alnical Trust	 460,000
	The
    Asdan and Uber Ltd. Trust	 153,800
	The
    Krial Trust	 11,808
	Rick
    Ferreira	 40,000
	Paul
    Stephaic	 16,000
	Tony
                                         Knight

        Purple
        Labs LLC

        Stuart
        Melnick
	16,000

        6,000

        4,000

	Phillippe
    Naim	48,000
	Ann
    Parkson	39,267
	Terri
    Smith	16,000
	Laird
    Smith	16,000
	Chad
    Walker	5,000
	JR
    Huddleston	5,000
	Michael
    Spina	5,000

    	 

    	 

    

EXHIBIT
A

ADOPTION
AGREEMENT

This
Adoption Agreement (“Adoption Agreement”) is executed on ___________________, 20__, by the undersigned
(the “Holder”) pursuant to the terms of that certain Investor Rights Agreement dated as of August 29,
2018 (the “Agreement”), by and among Olaregen Therapeutix Inc. (the “Company”)
and certain of its Stockholders, as such Agreement may be amended hereafter. Capitalized terms used but not defined in this Adoption
Agreement will have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement,
the Holder agrees as follows.

1.1       Acknowledgement.
Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the “Stock”)
for one of the following reasons (Check the correct box):

		 ̈	As
                                         a transferee of Shares from a party in such party’s capacity as an “Investor”
                                         bound by the Agreement, and after such transfer, Holder will be considered an “Investor”
                                         and a “Stockholder” for all purposes of the Agreement.

		 ̈	As
                                         a transferee of Shares from a party in such party’s capacity as a “Key Holder”
                                         bound by the Agreement, and after such transfer, Holder will be considered a “Key
                                         Holder” and a “Stockholder” for all purposes of the Agreement.

		 ̈	As
                                         a new Investor in accordance with Subsection 10.1(a) of the Agreement, in which
                                         case Holder will be an “Investor” and a “Stockholder” for all
                                         purposes of the Agreement.

		 ̈	In
                                         accordance with Subsection 10.1(b) of the Agreement, as a new party who is not
                                         a new Investor, in which case Holder will be a “Stockholder” for all purposes
                                         of the Agreement. 

1.2       Agreement.
Holder hereby (a) agrees that the Stock and any other shares of capital stock or securities required by the Agreement to be bound
thereby, will be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with the same force and effect
as if Holder were originally a party thereto.

1.3       Notice.
Any notice required or permitted by the Agreement will be given to Holder at the address listed below Holder’s signature
hereto.

HOLDER:
ACCEPTED AND AGREED:

 

By:
OLAREGEN THERAPEUTIX INC.

Name
and Title of Signatory

 

Address:
By: 

 

Title:
       

 

Email
Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]